Key result
Metabolic syndrome was associated with higher levels of sCD40L, IL-6, and thrombotic markers than controls, with strong correlations between sCD40L and IL-6 (r=0.67, p=0.003) and TF (r=0.59, p=0.008).
Why the study?
Are levels of sCD40L, IL-6, and hemostatic parameters elevated in patients with metabolic syndrome with or without ischemic heart disease compared to healthy controls?
Case-Control (n=72)
Are levels of sCD40L, IL-6, and hemostatic parameters elevated in patients with metabolic syndrome with or without ischemic heart disease compared to healthy controls?
Patients with metabolic syndrome, particularly those with ischemic heart disease, have elevated levels of sCD40L, IL-6, and thrombotic markers, suggesting a link between the CD40-CD40L system and hypercoagulability.
Answers are grounded in this paper and cite their sources.
May indicate inflammatory-thrombotic interplay in metabolic syndrome; hypothesis-generating and should not yet change practice.
Soluble CD40 ligand (sCD40L, also known as CD154) is a marker for platelet activation which could increase coagulation and inflammation. In this case-control study, we aimed to assess the levels of plasma sCD40L, IL-6, and some hemostatic parameters in patients with metabolic syndrome (MetS) whether or not associated with overt ischemic heart disease (IHD). We measured plasma sCD40L (an index of platelet activation), interleukin (IL)-6 (a proinflammatory cytokine), and some hemostatic parameters (tissue factor [TF], thrombin–antithrombin [TAT] and D-dimer) in 47 patients with metabolic syndrome (21 with and 26 without overt IHD) versus 25 comparable healthy control subjects. Significantly higher levels of sCD40L, IL-6, and thrombotic markers (TF, D-dimer and TAT) were found in patients with metabolic syndrome compared to healthy controls. The levels of IL-6 and sCD40 were highest in patients with overt IHD. Strong positive correlations existed between sCD40L and IL-6 (r = 0.67, p = 0.003), TF (r = 0.59, p = 0.008), and platelets count (r = 0.64, p = 0.005). Higher levels of sCD40L, IL-6, and thrombotic markers exist in MetS patients, particularly those with IHD. The strong positive correlations between sCD40L and IL-6, TF, and platelets count support a link between the CD40–CD40L system and the underlying inflammatory and hypercoagulable state in MetS patients.
No takes yet. Share an insight, caveat, or question.
El-Shahhat et al. (2011) conducted a case-control in Metabolic syndrome (n=72). Metabolic syndrome vs. Healthy controls was evaluated on Plasma levels of sCD40L, IL-6, and hemostatic parameters (TF, TAT, and D-dimer). Metabolic syndrome was associated with higher levels of sCD40L, IL-6, and thrombotic markers than controls, with strong correlations between sCD40L and IL-6 (r=0.67, p=0.003) and TF (r=0.59, p=0.008).
Synapse has enriched 10 related papers. Consider them for comparative context: